Atlas market file · Equity · United States
CuriosityStream Inc.CURI
- Last close
- 2.68
- Change
- +2.68%
- 96-bar range
- 2.3 – 3.53
- As of
- 6 Aug 2026
CuriosityStream Inc. is a services-motion picture & video tape production issuer listed as CURI on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+127.12% over the window).
Source rail: Yahoo Finance chart API (CURI). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for CURI. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
CURI public profile
Services-motion picture & video tape production issuer. CuriosityStream Inc. is connected to current market context, cited company sources and its retained research file.
CuriosityStream Inc. trades as CURI on NASDAQ. CuriosityStream Inc. (CURI) has a latest verified close of 2.68, up 2.68%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files CURI under USA Stocks for browsing.
What changed for CuriosityStream Inc. today
CuriosityStream Inc. is a streaming platform selling non-fiction and documentary content under the Curiosity brand, with its latest 10-Q showing revenue of $15.2 million for the quarter ending 31 March 2026. That figure sits awkwardly next to a July 8-K that boasts of "more than $10 million" in new third-party deals expected to land in the future. The company’s net loss was $1.3 million for the same quarter, and its diluted EPS came in at negative two cents. The operating loss was $1.5 million, while operating cash flow managed a modest $1.2 million inflow. Cash and equivalents stood at $16.9 million, with short-term investments of $3.5 million, giving the business a liquidity buffer of around $20.4 million against liabilities of $32.7 million. (source: CURI 10-Q (2026-03-31), https://www.sec.gov/Archives/edgar/data/1776909/000162828026043613/xslF345X06/wk-form4_1781644129.xml)
The company’s operating model is straightforward: license and distribute documentary and educational content to subscribers and third-party platforms. Curiosity, Inc., a wholly owned subsidiary, inked new agreements in Q2 2026 that management claims will generate over $10 million in additional revenue. The catch? These are forward-looking statements, and the company’s track record shows a gap between forecasts and realised results. The business does not disclose subscriber numbers, churn rates, or content production budgets in its filings, so gauging customer traction relies on reading between lines that are themselves written in cautious legalese. (source: CURI 8-K (2026-07-01), https://www.sec.gov/Archives/edgar/data/1776909/000162828026046365/curi-20260701.htm)
The June S-8 shelf registration allows the company to sell up to a theoretical ceiling of securities, though the filing explicitly notes that the registration will deregister any unsold shares once the offering terminates. The plain language reads like a disclaimer wrapped around a sales pitch. Meanwhile, two Form 4 filings on 16 June show insiders transacting under Rule 10b5-1 plans, which is standard practice but does little to address the company’s cash burn and reliance on future deals. The most concrete recent sale is a Form 144 filed on 12 June listing Hayden Phillip Brady as the seller, though the document does not disclose the number of shares or the sale price, treating those as disclosable only upon request. (source: CURI S-8 (2026-06-16), https://www.sec.gov/Archives/edgar/data/1776909/000121390026069332/ea0294700-s8_curiosity.htm; CURI 4 (2026-06-16), https://www.sec.gov/Archives/edgar/data/1776909/000162828026043613/xslF345X06/wk-form4_1781644129.xml; CURI 144 (2026-06-12), https://www.sec.gov/Archives/edgar/data/1776909/000195917326004594/xsl144X01/primary_doc.xml)
There is The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The company’s SEC filings are the sole product rail for market scrutiny, and they show a business whose liquidity is manageable but whose path to profitability hinges on deals yet to be realised. The absence of a detailed segment breakdown, subscriber metrics, or content cost disclosures limits visibility into unit economics. (source: CURI SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1776909)
The company’s latest 8-K leans on management’s belief that new third-party agreements will deliver over $10 million in revenue, yet the 10-Q only confirms $15.2 million in total revenue for the quarter. The gap is stark enough that investors might wonder whether the $10 million is a real pipeline or a slide in a deck. The company’s cash position is solid in absolute terms but thin relative to liabilities, and the absence of capex data suggests the business is not investing heavily in new content or infrastructure. Without clearer disclosure on customer economics or realised revenue from the touted deals, the file remains a work in progress. (source: CURI 8-K (2026-07-01), https://www.sec.gov/Archives/edgar/data/1776909/000162828026046365/curi-20260701.htm)
Sources & evidence · 9 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
CURI technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on CURI
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep CURI research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
CURI FAQ
What is CuriosityStream Inc. (CURI)?CuriosityStream Inc. (CURI) has a latest verified close of 2.68, up 2.68%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
CuriosityStream Inc. (CURI) has a latest verified close of 2.68, up 2.68%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for CURI?CuriosityStream Inc. (CURI) has a latest verified close of 2.68, up 2.68%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks...
CuriosityStream Inc. (CURI) has a latest verified close of 2.68, up 2.68%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files CURI under USA Stocks for browsing.
How often is the CURI page updated?The CURI public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The CURI public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for CURI?The CURI file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:CURI. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The CURI file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:CURI. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on CURI?Yes. The workstation can open CURI, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open CURI, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this CURI page investment advice?No. The CURI page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The CURI page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →
CURI
Equity · evidence first